Learn About Prenatal Genetic Screening Options

What Prenatal Genetic Screening Is and Why It Matters

Prenatal genetic screening involves tests that look at a developing baby's DNA and chromosomes during pregnancy. These tests search for signs that a baby may have certain genetic conditions or birth defects. Screening is different from diagnosis—screening identifies risk, while diagnostic tests confirm whether a condition is actually present.

Genetic screening has become a standard part of prenatal care for many pregnant people. According to the American College of Obstetricians and Gynecologists, about 70 percent of pregnant people in the United States receive some form of prenatal screening. The purpose is to give parents information so they can make informed decisions about their pregnancy and prepare for birth.

Common conditions that screening tests look for include Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). These are chromosomal conditions where a baby has an extra or missing chromosome. Screening can also detect neural tube defects like spina bifida, which affect the brain and spinal cord. Some screening tests can identify other genetic conditions depending on the type of test used.

Knowing about screening options matters because each test has different timing, accuracy rates, and types of information it provides. Some tests can be done earlier in pregnancy than others. Some tests are non-invasive (no risk to the baby), while others carry a small risk. Understanding what each test does helps parents decide which screening options make sense for their situation.

Practical takeaway: Prenatal genetic screening provides information about potential genetic conditions. Talk with your doctor about when screening might happen during your pregnancy and what conditions each test looks for.

First Trimester Screening: Early Detection Options

First trimester screening happens between 11 and 14 weeks of pregnancy. This timeframe is important because it allows early detection and gives parents more time to consider their options. First trimester screening combines two types of tests: a blood test and an ultrasound.

The blood test measures two substances that the baby and placenta produce: PAPP-A (pregnancy-associated plasma protein-A) and hCG (human chorionic gonadotropin). Levels that are higher or lower than normal may indicate chromosomal problems. The ultrasound measurement, called nuchal translucency, measures the thickness of fluid behind the baby's neck. Babies with Down syndrome often have thicker fluid in this area.

When combined, these two components detect Down syndrome in about 85 to 90 percent of cases. The test also screens for Edwards syndrome and Patau syndrome. False positives do occur—meaning the test suggests a problem when the baby is actually fine. This happens in about 5 percent of cases, which is why positive screening results lead to further testing rather than a diagnosis.

First trimester screening is non-invasive, meaning it does not involve any procedures that could harm the baby. The blood test is simple, like any standard blood draw. The ultrasound is the same type used in regular pregnancy care. Neither test increases the risk of miscarriage.

One advantage of first trimester screening is timing. Results come back while the pregnancy is still early, giving parents more options to consider. If results are concerning, parents have time to arrange diagnostic testing or plan for a baby with special needs. Some parents choose additional screening or diagnostic tests to get more information.

Practical takeaway: First trimester screening combines a blood test and ultrasound between weeks 11 and 14. It has a detection rate of 85 to 90 percent for Down syndrome and is non-invasive with no miscarriage risk.

Second Trimester Screening and Quad Screen Tests

Second trimester screening happens between 15 and 22 weeks of pregnancy. The most common second trimester test is the quad screen (or quadruple marker test), which measures four substances in the mother's blood. These markers include hCG, uE3 (unconjugated estriol), AFP (alpha-fetoprotein), and inhibin A.

The quad screen detects Down syndrome in about 80 to 85 percent of cases. It also screens for Edwards syndrome and can help identify pregnancies at risk for neural tube defects like spina bifida. When AFP levels are very low or very high, this may suggest birth defects affecting the brain or spinal cord. A second trimester ultrasound often accompanies this blood test to look for physical signs of genetic conditions.

One benefit of second trimester screening is that it can be done if parents did not have first trimester screening. Some parents come to prenatal care later in pregnancy and miss the first trimester window. The second trimester quad screen provides screening information for these pregnancies. Second trimester screening is also non-invasive with no miscarriage risk.

A drawback of second trimester screening compared to first trimester screening is timing. Results come back later in pregnancy, when parents have fewer options available. If results suggest a problem, decisions become more complex because the pregnancy is further along. However, for parents who want screening information regardless of timing, second trimester tests provide valuable risk assessment.

Sequential and contingent screening combine first and second trimester results for better detection rates. Sequential screening gives parents results after both trimesters are complete. Contingent screening provides results after the first trimester and offers second trimester screening only to certain risk groups. These approaches can improve detection to 90 to 95 percent for Down syndrome.

Practical takeaway: The quad screen measures four blood markers between weeks 15 and 22. It detects Down syndrome in about 80 to 85 percent of cases and is non-invasive. It provides screening information for parents who start care later in pregnancy.

Non-Invasive Prenatal Testing (NIPT) and Cell-Free DNA Tests

Non-invasive prenatal testing (NIPT), also called cell-free DNA screening, is among the most accurate screening tests available. It can be performed as early as 9 to 10 weeks of pregnancy. This test analyzes DNA from the baby that circulates in the mother's blood. The baby's DNA naturally enters the maternal bloodstream through the placenta, making this test completely non-invasive with no miscarriage risk.

NIPT detects Down syndrome in 99 percent of cases, Edwards syndrome in 97 to 98 percent of cases, and Patau syndrome in 97 to 98 percent of cases. These detection rates are significantly higher than traditional screening tests. The false positive rate is also very low—less than 1 percent for Down syndrome. This means fewer pregnant people receive false alarms suggesting problems that do not actually exist.

NIPT tests also screen for sex chromosome abnormalities like Turner syndrome and Klinefelter syndrome, depending on which version of the test is used. Some versions can identify microdeletions—small missing pieces of chromosomes that cause conditions like DiGeorge syndrome. The range of conditions screened depends on which NIPT test a healthcare provider orders.

One consideration with NIPT is cost. Insurance coverage varies. Some insurance plans cover NIPT for all pregnant people, while others cover it only for people at higher risk. Out-of-pocket cost can range from several hundred to over a thousand dollars if not covered. Some companies offer NIPT at reduced costs. Cost should not prevent screening—traditional screening methods remain available and effective options.

NIPT does have limitations. The test cannot detect neural tube defects like spina bifida, so many healthcare providers recommend ultrasound at 18 to 22 weeks even when NIPT is done. For pregnancies with very low fetal fraction (not enough baby DNA in the sample), the test may be inconclusive and need to be repeated. Pregnancies with multiple babies may not be suitable for NIPT depending on the test type.

Practical takeaway: NIPT analyzes baby DNA in maternal blood starting at 9 to 10 weeks. It has very high detection rates (97 to 99 percent) and very low false positive rates (under 1 percent). It carries no miscarriage risk but may not be covered by all insurance plans.

Diagnostic Tests: When Screening Suggests Further Information Is Needed

Diagnostic tests provide definitive answers about whether a baby has a genetic condition. These tests are recommended when screening results suggest elevated risk. Diagnostic